Regarding metastatic melanoma, a study by Gopalakrishan et al. revealed that responders to anti-PD-1 therapy not only had a significantly higher diversity of bacteria in their gut microbiota, but also had a higher relative abundance of Clostridiales, Ruminococcaceae, and Faecalibacterium spp. The gene discussed is PDCD1; the disease is metastatic melanoma.